Making life-changing therapies available to those who need them most.

Access & affordability

Committed to improving access and affordability.

While exciting in its ability to cure the previously incurable, the biopharmaceutical revolution presents significant challenges for healthcare payers of all sizes.

For employers and health plans, managing specialty pharmacy and medical costs is their number one concern. The challenges of cell and gene therapies are especially frustrating — prices exceeding $4 million per treatment, coupled with unproven long-term durability of benefits and the inability to forecast new treatment claims.

Per Reuters, as of 2024 the average cost of newly approved drugs is more than $370,000, up significantly from prior years. This pace of cost growth is simply not sustainable, and it threatens the financial viability of healthcare benefits for millions of patients in the U.S. and many more around the world.

To make matters worse, financial solutions such as traditional stop-loss policies are not well-equipped to tackle these problems. PayRx is uniquely focused on delivering solutions that challenge these old paradigms. Our business model is designed to align our interests with those of our customers — when patients, providers and payers succeed, we do.

With decades of success in healthcare, technology and finance, our team of experts is committed to leading the market with solutions that outperform all others. That means approaching the challenges of this truly remarkable biopharmaceutical revolution differently.

For us, creating PayRx was about more than simply building a company. We are paving a new path in the healthcare ecosystem — to provide better health outcomes, affordability, and improved access to life-changing and curative therapies.